RBM 3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer 1 , 2

The RNA-binding motif protein 3 (RBM3) was initially discovered as a putative cancer biomarker based on its differential expression in various cancer forms in the Human Protein Atlas (HPA). We previously reported an association between high expression of RBM3 and prolonged survival in breast and epithelial ovarian cancer (EOC). Because the function of RBM3 has not been fully elucidated, the aim of this study was to use gene set enrichment analysis to identify the underlying biologic processes associated with RBM3 expression in a previously analyzed EOC cohort (cohort 1, n = 267). This revealed an association between RBM3 expression and several cellular processes involved in the maintenance of DNA integrity. RBM3-regulated genes were subsequently screened in the HPA to select for putative prognostic markers, and candidate proteins were analyzed in the ovarian cancer cell line A2780, whereby an up-regulation of Chk1, Chk2, and MCM3 was demonstrated in siRBM3-treated cells compared to controls. The prognostic value of these markers was assessed at the messenger RNA level in cohort 1 and the protein level in an independent EOC cohort (cohort 2, n = 154). High expression levels of Chk1, Chk2, and MCM3 were associated with a significantly shorter survival in both cohorts, and phosphorylated Chk2 was an adverse prognostic marker in cohort 2. These results uncover a putative role for RBM3 in DNA damage response, which might, in part, explain its cisplatin-sensitizing properties and good prognostic value in EOC. Furthermore, it is demonstrated that Chk1, Chk2, and MCM3 are poor prognostic markers in EOC. Translational Oncology (2011) 4, 212–22

[1]  Y. Wang,et al.  Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion , 2010, Oncogene.

[2]  Shilpi Arora,et al.  RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. , 2010, Gynecologic oncology.

[3]  Fredrik Ponten,et al.  Antibody-based proteomics: fast-tracking molecular diagnostics in oncology , 2010, Nature Reviews Cancer.

[4]  F. Pontén,et al.  Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer , 2010, Journal of Translational Medicine.

[5]  S. Narod.  Testing for CHEK2 in the cancer genetics clinic: ready for prime time? , 2010, Clinical genetics.

[6]  P. Conte,et al.  Achievements and unmet needs in the management of advanced ovarian cancer. , 2010, Gynecologic oncology.

[7]  M. Fernö,et al.  Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer , 2009, Modern Pathology.

[8]  Stephen Dunaway,et al.  The Schizosaccharomyces pombe Checkpoint Kinases Chk1 and Cds1 Are Important for Cell Survival in Response to Cisplatin , 2009, PloS one.

[9]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[10]  Å. Borg,et al.  Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer , 2008, Breast Cancer Research.

[11]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[12]  M. Broggini,et al.  Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil , 2008, Clinical Cancer Research.

[13]  R. Postier,et al.  Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe , 2008, Oncogene.

[14]  C. Lindskog,et al.  A Web-based Tool for in Silico Biomarker Discovery Based on Tissue-specific Protein Profiles in Normal and Cancer Tissues*S , 2008, Molecular & Cellular Proteomics.

[15]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[16]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[17]  C. Britten,et al.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.

[18]  J. Bartek,et al.  DNA damage signalling guards against activated oncogenes and tumour progression , 2007, Oncogene.

[19]  P. Vanderklish,et al.  Two isoforms of the cold‐inducible mRNA‐binding protein RBM3 localize to dendrites and promote translation , 2007, Journal of neurochemistry.

[20]  J. Bartek,et al.  DNA damage checkpoints: from initiation to recovery or adaptation. , 2007, Current opinion in cell biology.

[21]  F. Pontén,et al.  Analysis of Protein Expression in Cell Microarrays: A Tool for Antibody-based Proteomics , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  A. Eggermont,et al.  Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.

[23]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[25]  M. Lei.  The MCM complex: its role in DNA replication and implications for cancer therapy. , 2005, Current cancer drug targets.

[26]  F. Pontén,et al.  Antibody-based Proteomics for Human Tissue Profiling , 2005, Molecular & Cellular Proteomics.

[27]  Gerald M Edelman,et al.  Cold stress-induced protein Rbm3 binds 60S ribosomal subunits, alters microRNA levels, and enhances global protein synthesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[29]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[30]  L. Poellinger,et al.  Induction of ID2 Expression by Hypoxia-inducible Factor-1 , 2004, Journal of Biological Chemistry.

[31]  J. Bartek,et al.  ATR, Claspin and the Rad9-Rad1-Hus1 Complex Regulate Chk1 and Cdc25A in the Absence of DNA Damage , 2004, Cell cycle.

[32]  R. Kirschner,et al.  Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism , 2004, Journal of Cell Science.

[33]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[34]  S. Forsburg,et al.  MCM proteins: DNA damage, mutagenesis and repair. , 2004, Current opinion in genetics & development.

[35]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[36]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[37]  S. Dellis,et al.  Vaccinia Virus Late Transcription Is Activated in Vitro by Cellular Heterogeneous Nuclear Ribonucleoproteins* , 2001, The Journal of Biological Chemistry.

[38]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[39]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[40]  M. Nakanishi,et al.  Cell cycle-dependent and ATM-independent expression of human Chk1 kinase , 1999, Oncogene.

[41]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[42]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[43]  U. Francke,et al.  RBM3, a novel human gene in Xp11.23 with a putative RNA-binding domain. , 1995, Human molecular genetics.

[44]  C. Burd,et al.  Conserved structures and diversity of functions of RNA-binding proteins. , 1994, Science.

[45]  K. Seeger,et al.  The RNA-Binding Protein RBM3 Is Required for Cell Proliferation and Protects Against Serum Deprivation-Induced Cell Death , 2010, Pediatric Research.

[46]  L. Sutherland,et al.  RNA binding motif (RBM) proteins: A novel family of apoptosis modulators? , 2005, Journal of cellular biochemistry.

[47]  A. Söling,et al.  Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .